Fresenius Kabi intros Aloxi alternative
Fresenius Kabi has launched its Aloxi alternative (palonosetron HCl). The drug is indicated to treat and prevent chemotherapy-induced nausea.
Fresenius Kabi’s Aloxi alternative is available in single-dose vials of 0.25 mg/5 ml dosage strength. The product joins Lake Zurich, Ill.-based Fresenius Kabi’s other medications for infusions, transfusion and clinical nutrition.
“The addition of palonosetron to the injectable antiemetic medicines offered by Fresenius Kabi is the latest example of our commitment to offer a large product portfolio to meet the diverse needs of clinicians and patients,” Fresenius Kabi president and CEO John Ducker said.
No comments found